T-cell subpopulation in patients with metastatic renal cell carcinoma treated by recombinant interleukin-2, recombinant interferon-alpha, 5-fluorouracil, and vinblastine

T-cell subpopulations were evaluated in 10 patients with metastatic renal c ell carcinoma treated with recombinant interleukin-2, recombinant interfero n-alpha 5-fluorouracil, and vinblastine. T-cell subpopulation was tested by flow cytometry, and the results were compared with healthy control subject s. Mean T-cell values before treatment as compared with control were as fol lows: CD3, 68 vs. 73%; CD4, 34 vs. 53%; CD8, 38 vs. 31%; CD4/CD8, 1.1 vs. 1 .8; CD4CD69, 20 vs. 47%, and CD8CD69, 24 vs. 19%. The difference in CD4, CD 4/CD8, and CD4CD69 was statistically significant After treatment (8 weeks), the values of CD4/CD8 ratio and CD4CD69 increased. Three patients achieved complete response, two partial response, and two had stabilization of the disease. After treatment, the CD4/CD8 ratio increased in complete responder s, from 1.1 to 2.0, and CD4CD69 increased in complete and partial responder s, from 11 to 37% and 23 to 31%, respectively. in nonresponders, no similar change was observed. In conclusion, increases in CD4/CD8 ratio and CD4CD69 levels in metastatic renal cell carcinoma patients may be associated with response to immunochemotherapy.